Unknown

Dataset Information

0

Complete Molecular Weight Profiling of Low-Molecular Weight Heparins Using Size Exclusion Chromatography-Ion Suppressor-High-Resolution Mass Spectrometry.


ABSTRACT: Low-molecular weight heparins (LMWH) prepared by partial depolymerization of unfractionated heparin are used globally to treat coagulation disorders on an outpatient basis. Patent protection for several LMWH has expired and abbreviated new drug applications have been approved by the Food and Drug Administration. As a result, reverse engineering of LMWH for biosimilar LMWH has become an active global endeavor. Traditionally, the molecular weight distributions of LMWH preparations have been determined using size exclusion chromatography (SEC) with optical detection. Recent advances in liquid chromatography-mass spectrometry methods have enabled exact mass measurements of heparin saccharides roughly up to degree-of-polymerization 20, leaving the high molecular weight half of the LMWH preparation unassigned. We demonstrate a new LC-MS system capable of determining the exact masses of complete LMWH preparations, up to dp30. This system employed an ion suppressor cell to desalt the chromatographic effluent online prior to the electrospray mass spectrometry source. We expect this new capability will impact the ability to define LMWH mixtures favorably.

SUBMITTER: Zaia J 

PROVIDER: S-EPMC5111364 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Complete Molecular Weight Profiling of Low-Molecular Weight Heparins Using Size Exclusion Chromatography-Ion Suppressor-High-Resolution Mass Spectrometry.

Zaia Joseph J   Khatri Kshitij K   Klein Joshua J   Shao Chun C   Sheng Yuewei Y   Viner Rosa R  

Analytical chemistry 20161017 21


Low-molecular weight heparins (LMWH) prepared by partial depolymerization of unfractionated heparin are used globally to treat coagulation disorders on an outpatient basis. Patent protection for several LMWH has expired and abbreviated new drug applications have been approved by the Food and Drug Administration. As a result, reverse engineering of LMWH for biosimilar LMWH has become an active global endeavor. Traditionally, the molecular weight distributions of LMWH preparations have been determ  ...[more]

Similar Datasets

| S-EPMC6272732 | biostudies-literature
| S-EPMC6545233 | biostudies-literature
| S-EPMC7081181 | biostudies-literature
| S-EPMC8943524 | biostudies-literature
| S-EPMC5053037 | biostudies-literature
| S-EPMC3612379 | biostudies-literature
| S-EPMC4966600 | biostudies-literature
2022-10-27 | GSE212408 | GEO
| S-EPMC6156775 | biostudies-literature
2021-05-17 | PXD026034 |